Oscar Health, Inc. Class A Common Stock (OSCR) Stock Analysis — Latest Investor Quotes & Trade Calls

Buy Opportunity: Oscar Health Below $14

+7.53%current return

"okay, we've had a pullback in in the health care companies. Why? Because Trump says they charge too much. They make too much money. Oh, shocking. You know, think about health care. Healthcare needs to make the way they make money is by either cutting services or charging you more. One or the other. So, this is Oscar. I love the price slider. Okay. the most traded price uh since the IPO on the average cost of every buyer since IPO are lined up around $14.70. Guess what? You know, you can buy this one under I think 14. We'll look at this chart, but it's literally telling you the point of control since IPO is $14.70. You want to buy under that VWAP volume weighted average price."

The speaker emphasizes a technical opportunity in Oscar Health, noting that the average buyer cost since IPO centers around $14.70. He suggests that buying the stock under $14, potentially around 13.15, could offer a favorable risk/reward profile.

"Maintaining a $30 price target for OSCR by end of 2026, contingent on continued Medical Loss Ratio improvement and modest revenue growth."

Maintaining a $30 price target for OSCR by end of 2026, contingent on continued Medical Loss Ratio improvement and modest revenue growth.

"OSCR (overview): Tech-driven ACA insurer with 2M members. Recent Q1 profit ($275M on $3B rev), but slashed 2025 outlook by $500M due to rising medical costs. Under ex-Aetna CEO Bertolini, achieved first annual profit in 2024 ($25M). Bull: tech platform, 45% YoY growth, 81.7% MLR. Bear: regulatory risk, ACA dependence, thin margins."

"OSCR: Insurer disrupting healthcare via tech platform. Record profits in Q1 2025 ($275M) with 2M+ members. Major upside from ICHRA model expanding addressable market from 21M to 75M customers ($720B premium volume). 97% revenue from ACA poses risk if subsidies expire 2025. 20% CAGR target with 5% margins by 2027. Fast growth (EPS +226% next 2yrs) at reasonable valuation (P/E 31)."

"OSCR: Trading at 0.4x P/S due to ACA subsidy renewal fears, but 64% of members in red states make Republican cuts unlikely. 2M members added in 15 months signals strong value proposition. Improving MLR (75.4% Q1'25) & declining SG&A (15.8%) show operational efficiency. 8-10x P/S fair value = 20x upside. Executing 'Costco Algorithm' in healthcare."

"OSCR (overview): Health insurer + tech platform trading at 35x fwd P/E. Bull: 40% YoY revenue growth, profitable Q1 2025, strong cash position, AI-driven efficiency (lowest SG&A ratio ever), '+Oscar Platform' diversification. Bear: ACA subsidy expiration Dec 2025, competition from UnitedHealth/Anthem/Centene, MLR volatility, payment delay allegations."